While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the ...

These officials were thrilled Oct. 29 when FDA Commissioner Marty Makary announced the agency's plan, which he said would halve the time and money needed to get what are called "biosimilar" drugs to ...